Published in J Clin Oncol on February 01, 2001
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med (2003) 14.59
Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst (2009) 4.36
Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc Natl Acad Sci U S A (2007) 4.08
Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol (2010) 2.41
Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. Nat Rev Clin Oncol (2009) 2.41
Biomarkers of angiogenesis and their role in the development of VEGF inhibitors. Br J Cancer (2009) 1.78
Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. J Clin Oncol (2010) 1.65
Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models. Proc Natl Acad Sci U S A (2001) 1.58
CD133 positive endothelial progenitor cells contribute to the tumour vasculature in non-small cell lung cancer. J Clin Pathol (2004) 1.57
Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy. Nat Rev Clin Oncol (2009) 1.55
The VEGF family in cancer and antibody-based strategies for their inhibition. MAbs (2011) 1.41
Balancing risk in ophthalmic prescribing: assessing the safety of anti-VEGF therapies and the risks associated with unlicensed medicines. Graefes Arch Clin Exp Ophthalmol (2012) 1.40
Long-term multiple-dose pharmacokinetics of human monoclonal antibodies (MAbs) against human immunodeficiency virus type 1 envelope gp120 (MAb 2G12) and gp41 (MAbs 4E10 and 2F5). Antimicrob Agents Chemother (2006) 1.27
Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target? Oncologist (2010) 1.27
ZD6474--clinical experience to date. Br J Cancer (2005) 1.23
Increase of plasma VEGF after intravenous administration of bevacizumab is predicted by a pharmacokinetic model. Cancer Res (2010) 1.22
Anti-VEGF therapies in the clinic. Cold Spring Harb Perspect Med (2012) 1.20
A phase I study of sunitinib plus bevacizumab in advanced solid tumors. Clin Cancer Res (2009) 1.19
A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma. J Natl Compr Canc Netw (2011) 1.16
Angiogenesis inhibitors in clinical development; where are we now and where are we going? Br J Cancer (2004) 1.15
Predicting the effects of anti-angiogenic agents targeting specific VEGF isoforms. AAPS J (2012) 1.14
A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108. Leuk Lymphoma (2009) 1.14
What is the risk of intracranial bleeding during anti-VEGF therapy? Neuro Oncol (2008) 1.13
Vascular endothelial growth factor levels in immunodepleted plasma of cancer patients as a possible pharmacodynamic marker for bevacizumab activity. J Clin Oncol (2007) 1.12
Pharmacodynamic study using FLT PET/CT in patients with renal cell cancer and other solid malignancies treated with sunitinib malate. Clin Cancer Res (2011) 1.08
Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer. Br J Cancer (2011) 1.07
Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer. J Neurooncol (2010) 1.04
Ten years of anti-vascular endothelial growth factor therapy. Nat Rev Drug Discov (2016) 1.03
New approaches in angiogenic targeting for colorectal cancer. World J Gastroenterol (2007) 1.03
Present and future evolution of advanced breast cancer therapy. Breast Cancer Res (2010) 1.01
VEGF inhibitors and prostate cancer therapy. Curr Mol Pharmacol (2009) 0.99
Phase I safety, pharmacokinetic, and pharmacodynamic study of ENMD-2076, a novel angiogenic and Aurora kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res (2010) 0.98
Pharmacokinetics and pharmacodynamics of VEGF-neutralizing antibodies. BMC Syst Biol (2011) 0.98
Laparoscopic radical nephrectomy after shrinkage of a caval tumor thrombus with sunitinib. Nat Rev Urol (2009) 0.94
Molecularly targeted therapy for metastatic colon cancer: proven treatments and promising new agents. Gastrointest Cancer Res (2011) 0.93
Tumour matrilysin expression predicts metastatic potential of stage I (pT1) colon and rectal cancers. Gut (2005) 0.93
Treatment for colorectal liver metastases: a review. Langenbecks Arch Surg (2009) 0.93
Skin rash associated with intravitreal bevacizumab in a patient with macular choroidal neovascularization. Clin Ophthalmol (2009) 0.93
Bevacizumab-based therapies in the first-line treatment of metastatic colorectal cancer. Oncologist (2012) 0.92
Very low dose bevacizumab for the treatment of epistaxis in patients with hereditary hemorrhagic telangiectasia. Allergy Rhinol (Providence) (2014) 0.92
Bevacizumab treatment for advanced breast cancer. Oncologist (2011) 0.90
The role of vascular endothelial growth factor in the pathogenesis, diagnosis and treatment of malignant pleural effusion. Curr Oncol Rep (2013) 0.90
Kinase inhibitors and monoclonal antibodies in oncology: clinical implications. Nat Rev Clin Oncol (2015) 0.90
Efficacy, safety, and biomarkers of single-agent bevacizumab therapy in patients with advanced hepatocellular carcinoma. Oncologist (2012) 0.90
Anti-tumor effect of CT-322 as an adnectin inhibitor of vascular endothelial growth factor receptor-2. MAbs (2011) 0.90
Bevacizumab for the treatment of glioblastoma. Clin Med Insights Oncol (2013) 0.90
Bevacizumab in the treatment of five patients with breast cancer and brain metastases: Japan Breast Cancer Research Network-07 trial. Onco Targets Ther (2012) 0.89
A phase I trial and pharmacokinetic study of aflibercept (VEGF Trap) in children with refractory solid tumors: a children's oncology group phase I consortium report. Clin Cancer Res (2012) 0.89
The effect of anti-VEGF drugs (bevacizumab and aflibercept) on the survival of patients with metastatic colorectal cancer (mCRC). Onco Targets Ther (2012) 0.89
Human antibodies targeting the C-type lectin-like domain of the tumor endothelial cell marker clec14a regulate angiogenic properties in vitro. Oncogene (2013) 0.89
Transarterial chemoembolization plus or minus intravenous bevacizumab in the treatment of hepatocellular cancer: a pilot study. BMC Cancer (2012) 0.89
Computational modeling of tumor response to vascular-targeting therapies--part I: validation. Comput Math Methods Med (2011) 0.88
Therapeutic antibodies against cancer. Hematol Oncol Clin North Am (2012) 0.87
Targeting angiogenesis in esophagogastric adenocarcinoma. Oncologist (2011) 0.87
Antiangiogenic therapies in early-stage breast cancer. Clin Breast Cancer (2010) 0.86
Pilot trial of preoperative (neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed estrogen receptor- or progesterone receptor-positive breast cancer. Clin Breast Cancer (2010) 0.86
Anti-angiogenic therapies for metastatic colorectal cancer: current and future perspectives. World J Gastroenterol (2013) 0.85
Endothelial cells in dengue hemorrhagic fever. Antiviral Res (2014) 0.85
In pursuit of new anti-angiogenic therapies for cancer treatment. Front Biosci (Landmark Ed) (2011) 0.85
Cancer therapy and cardiovascular risk: focus on bevacizumab. Cancer Manag Res (2015) 0.84
Targeted therapies for pancreatic cancer. Br Med Bull (2008) 0.84
Application of quantitative pharmacology in development of therapeutic monoclonal antibodies. AAPS J (2010) 0.84
Targeted therapies in the management of renal cell carcinoma: role of bevacizumab. Biologics (2008) 0.84
A pharmacokinetic binding model for bevacizumab and VEGF165 in colorectal cancer patients. Cancer Chemother Pharmacol (2015) 0.84
A pilot study of antiangiogenic therapy with bevacizumab and thalidomide in patients with metastatic renal cell carcinoma. J Immunother (2004) 0.83
Genetic and epigenetic alterations in breast cancer: what are the perspectives for clinical practice? Int J Biochem Cell Biol (2007) 0.82
Pharmacokinetics and pharmacodynamics of rilotumumab: a decade of experience in preclinical and clinical cancer research. Br J Clin Pharmacol (2015) 0.82
Current targeted therapies in the treatment of advanced colorectal cancer: a review. Ther Adv Med Oncol (2016) 0.81
Future of targeted agents in metastatic colorectal cancer. Colorectal Cancer (2012) 0.81
Hepatic arterial infusion of bevacizumab in combination with oxaliplatin reduces tumor growth in a rat model of colorectal liver metastases. Clin Exp Metastasis (2011) 0.81
Personalizing colon cancer therapeutics: targeting old and new mechanisms of action. Pharmaceuticals (Basel) (2013) 0.81
Phase I, pharmacokinetic, and biological studies of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, administered after meals with solid tumors. Cancer Chemother Pharmacol (2010) 0.81
Phase I and pharmacokinetic study of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, by twice daily oral administration between meals in patients with advanced solid tumors. Cancer Chemother Pharmacol (2010) 0.81
Computational modelling of anti-angiogenic therapies based on multiparametric molecular imaging data. Phys Med Biol (2012) 0.81
Bevacizumab in metastatic breast cancer: when may it be used? Ther Adv Med Oncol (2011) 0.80
Pharmacodynamic study of axitinib in patients with advanced malignancies assessed with (18)F-3'deoxy-3'fluoro-L-thymidine positron emission tomography/computed tomography. Cancer Chemother Pharmacol (2015) 0.80
Recent translational research: antiangiogenic therapy for breast cancer - where do we stand? Breast Cancer Res (2004) 0.80
Targeted therapy of advanced non-small cell lung cancer: the role of bevacizumab. Biologics (2007) 0.80
Cardio-Oncology: How New Targeted Cancer Therapies and Precision Medicine Can Inform Cardiovascular Discovery. Circulation (2015) 0.80
Circulating biomarkers in advanced colorectal cancer patients randomly assigned to three bevacizumab-based regimens. Cancers (Basel) (2014) 0.80
FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study. Ann Oncol (2015) 0.79
Greater efficacy of chemotherapy plus bevacizumab compared to chemo- and targeted therapy alone on non-small cell lung cancer patients with brain metastasis. Oncotarget (2016) 0.79
The place of VEGF inhibition in the current management of renal cell carcinoma. Br J Cancer (2006) 0.79
Questions regarding the optimal use of bevacizumab in glioblastoma: a moving target. Neuro Oncol (2014) 0.79
Bevacizumab in the treatment of HER2-negative breast cancer. Biologics (2008) 0.78
Targeted therapies in the management of colorectal carcinoma: role of bevacizumab. Onco Targets Ther (2009) 0.78
An update in the use of antibodies to treat glioblastoma multiforme. Autoimmune Dis (2013) 0.78
Interspecies scaling and prediction of human clearance: comparison of small- and macro-molecule drugs. Xenobiotica (2011) 0.78
The bevacizumab experience in advanced renal cell carcinoma. Onco Targets Ther (2010) 0.78
Impact of preoperative targeted therapy on postoperative complications after resection of colorectal liver metastases. Int J Colorectal Dis (2011) 0.78
Treatment of exudative age-related macular degeneration: many factors to consider. Am J Ophthalmol (2007) 0.78
Targeted therapeutic agents for colorectal cancer. Gastroenterol Clin North Am (2010) 0.78
Anti-VEGF Therapy and the Retina: An Update. J Ophthalmol (2015) 0.78
Atypical reversible posterior leukoencephalopathy syndrome (RPLS) induced by cediranib in a patient with metastatic rectal cancer. Invest New Drugs (2014) 0.78
Modeling of growth factor-receptor systems from molecular-level protein interaction networks to whole-body compartment models. Methods Enzymol (2009) 0.77
Outcomes of patients with advanced non-small cell lung cancer treated in a phase I clinic. Oncologist (2011) 0.77
Safety of bevacizumab 7.5 mg/kg infusion over 10 minutes in NSCLC patients. Invest New Drugs (2011) 0.77
Phase I study of enzastaurin and bevacizumab in patients with advanced cancer: safety, efficacy and pharmacokinetics. Invest New Drugs (2012) 0.77
In vitro models of cancer stem cells and clinical applications. BMC Cancer (2016) 0.77
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med (2001) 44.67
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med (2001) 24.51
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med (2001) 11.88
Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol (1999) 11.78
High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol (1999) 10.86
A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med (2013) 6.67
The biology of chronic myeloid leukemia. N Engl J Med (1999) 4.80
Minimally important differences were estimated for the Functional Assessment of Cancer Therapy-Colorectal (FACT-C) instrument using a combination of distribution- and anchor-based approaches. J Clin Epidemiol (2005) 4.29
Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth. Mol Cell Biol (1997) 3.76
A synthetic IgG-binding domain based on staphylococcal protein A. Protein Eng (1989) 3.31
Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol (2001) 3.06
The molecular genetics of Philadelphia chromosome-positive leukemias. N Engl J Med (1988) 2.93
Should polymerase chain reaction analysis to detect minimal residual disease in patients with chronic myelogenous leukemia be used in clinical decision making? Blood (1999) 2.79
Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia (2006) 2.66
A preliminary study of aerosolized recombinant human deoxyribonuclease I in the treatment of cystic fibrosis. N Engl J Med (1992) 2.57
Efficacy and safety of short-term administration of aerosolised recombinant human DNase I in adults with stable stage cystic fibrosis. Lancet (1993) 2.50
Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients. J Clin Oncol (1987) 2.12
Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival. Ann Oncol (2003) 2.08
Allogeneic hematopoietic stem cell transplantation and norovirus gastroenteritis: a previously unrecognized cause of morbidity. Clin Infect Dis (2009) 2.04
The treatment of systemic lupus erythematosus (SLE) in NZB/W F1 hybrid mice; studies with recombinant murine DNase and with dexamethasone. Clin Exp Immunol (1996) 1.94
Induction of classical transplantation tolerance in the adult. J Exp Med (1989) 1.91
Chronic myelogenous leukemia: biology and therapy. Ann Intern Med (1999) 1.87
Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia. N Engl J Med (1986) 1.86
Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol (2001) 1.84
The Snark is a Boojum: the continuing problem of drug resistance in the antiangiogenic era. Ann Oncol (2003) 1.83
Apolipoprotein E genes in Lewy body and Parkinson's disease. Lancet (1994) 1.77
Pattern of neurobehavioral deficits associated with interferon alfa therapy for leukemia. Neurology (1995) 1.71
Prognostic value of serum interleukin-6 in diffuse large-cell lymphoma. Ann Intern Med (1997) 1.71
Treatment of myelogenous leukemia: current status and investigational options. Blood (1996) 1.70
Malignancy-associated Sweet's syndrome: review of the world literature. J Clin Oncol (1988) 1.66
Comparison of competitive-nested PCR and real-time PCR in detecting BCR-ABL fusion transcripts in chronic myeloid leukemia patients. Leukemia (2002) 1.62
Low molecular weight RNA species from chromatin. Biochemistry (1975) 1.62
Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer (1988) 1.62
First-line Herceptin monotherapy in metastatic breast cancer. Oncology (2001) 1.60
Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J Clin Oncol (2001) 1.58
Paclitaxel sensitivity of breast cancer cells with constitutively active NF-kappaB is enhanced by IkappaBalpha super-repressor and parthenolide. Oncogene (2000) 1.57
Airway epithelial CFTR mRNA expression in cystic fibrosis patients after repetitive administration of a recombinant adenovirus. J Clin Invest (1999) 1.56
Methylation of the ABL1 promoter in chronic myelogenous leukemia: lack of prognostic significance. Blood (1999) 1.55
Physiology and pathophysiology of dendritic cells. Hum Pathol (1997) 1.54
Monoclonal antibody identification and characterization of a Mr 43,000 membrane glycoprotein associated with human breast cancer. Cancer Res (1986) 1.53
Serum levels of interleukin-10 in patients with diffuse large cell lymphoma: lack of correlation with prognosis. Blood (1995) 1.52
Clinical toxicity of interferons in cancer patients: a review. J Clin Oncol (1986) 1.50
A glycan-phosphatidylinositol-specific phospholipase D in human serum. Science (1987) 1.50
Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. Leukemia (2008) 1.49
Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service. Ann Intern Med (1995) 1.48
Rhizobium meliloti anthranilate synthase gene: cloning, sequence, and expression in Escherichia coli. J Bacteriol (1989) 1.47
A new xenograft model of myeloma bone disease demonstrating the efficacy of human mesenchymal stem cells expressing osteoprotegerin by lentiviral gene transfer. Leukemia (2007) 1.47
Spreading of human neutrophils is immediately preceded by a large increase in cytoplasmic free calcium. Proc Natl Acad Sci U S A (1986) 1.45
Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: five-year follow-up of the Cytokine Working Group Study. Cancer J Sci Am (1997) 1.45
Colonic adenomas in asymptomatic women with a history of breast cancer. Am J Gastroenterol (1993) 1.44
Omega-oxidation is the major pathway for the catabolism of leukotriene B4 in human polymorphonuclear leukocytes. J Biol Chem (1984) 1.44
Cost-effectiveness of interferon-alpha and conventional chemotherapy in chronic myelogenous leukemia. Ann Intern Med (1996) 1.43
Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation. J Clin Invest (1993) 1.43
Recombinant human DNase inhalation in normal subjects and patients with cystic fibrosis. A phase 1 study. JAMA (1992) 1.43
A gene fusion system for generating antibodies against short peptides. Gene (1987) 1.42
The human cellular abl gene product in the chronic myelogenous leukemia cell line K562 has an associated tyrosine protein kinase activity. Virology (1985) 1.41
Chronic myelogenous leukemia: a concise update. Blood (1993) 1.40
A phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients. J Clin Oncol (1988) 1.36
Cooperative effects by the initiation codon and its flanking regions on translation initiation. Gene (2001) 1.33
Chronic immune stimulation by sperm alloantigens. Support for the hypothesis that spermatozoa induce immune dysregulation in homosexual males. JAMA (1984) 1.31
CD4 monoclonal antibody pairs for immunosuppression and tolerance induction. Eur J Immunol (1987) 1.31
Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma. J Clin Oncol (1995) 1.30
Characterization of a messenger RNA polynucleotide vaccine vector. Cancer Res (1995) 1.30
Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients. Am J Med (1987) 1.30
Characterization of a succinate dehydrogenase complex solubilized from the cytoplasmic membrane of Bacillus subtilis with the nonionic detergent Triton X-100. J Bacteriol (1979) 1.29
Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood (1989) 1.29
A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma. Cancer (1989) 1.27
Characterization of succinic dehydrogenase mutants of Bacillus subtilis by crossed immunoelectrophoresis. J Bacteriol (1978) 1.27
Long-term follow-up of 23 patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with allogeneic bone marrow transplant in first complete remission. Leukemia (1999) 1.26
Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia. Blood (1998) 1.26
Homoharringtonine: history, current research, and future direction. Cancer (2001) 1.25
The Reaction Level Scale (RLS85). Manual and guidelines. Acta Neurochir (Wien) (1988) 1.24
Rhabdomyosarcoma of the nose and paranasal sinuses in adults and children. Otolaryngol Head Neck Surg (1995) 1.24
Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer. Br J Cancer (2011) 1.24
First-line, single-agent Herceptin(R) (trastuzumab) in metastatic breast cancer. a preliminary report. Eur J Cancer (2001) 1.23
Caspase 2 and caspase 3 protein levels as predictors of survival in acute myelogenous leukemia. Blood (1998) 1.22
Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia. Leukemia (2010) 1.22
Benign methylmalonic aciduria. N Engl J Med (1984) 1.22
Taxanes in the treatment of breast cancer: a prodigy comes of age. Cancer Invest (1999) 1.19
Efficient secretion and purification of human insulin-like growth factor I with a gene fusion vector in Staphylococci. Nucleic Acids Res (1985) 1.18
Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase. Blood (1995) 1.18
Chronic myelogenous leukemia: a review. Am J Med (1996) 1.18
Identification of molecular variants of p210bcr-abl in chronic myelogenous leukemia. Blood (1987) 1.18
Deafness from furosemide. Ann Intern Med (1970) 1.18
A new familial immunodeficiency disorder characterized by severe neutropenia, a defective marrow release mechanism, and hypogammaglobulinemia. Am J Med (1990) 1.17
Clinical investigation of human alpha interferon in chronic myelogenous leukemia. Blood (1987) 1.17
Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma. J Clin Oncol (2001) 1.16
Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma. J Clin Oncol (1993) 1.16
Prognosis of chronic lymphocytic leukemia: a multivariate regression analysis of 325 untreated patients. Blood (1987) 1.15
Leukotriene B4 omega-hydroxylase in human polymorphonuclear leukocytes. Partial purification and identification as a cytochrome P-450. J Clin Invest (1985) 1.15
Inhibition of proliferation and induction of apoptosis by doxycycline in cultured human osteosarcoma cells. J Lab Clin Med (1997) 1.15
Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia. Blood (1983) 1.15
Sensitivity and specificity of pooled versus individual sera in a human immunodeficiency virus antibody prevalence study. J Clin Microbiol (1989) 1.14
Role of heme in synthesis and membrane binding of succinic dehydrogenase in Bacillus subtilis. J Bacteriol (1979) 1.14
Prostaglandin I2 is not a major metabolite of arachidonic acid in cultured endothelial cells from human foreskin microvessels. J Clin Invest (1984) 1.14